Criteria for Recognition and Approval of a Novel PGY2 Residency in a New Advanced Area of Practice and Demonstration Approval Process

Background

3.2.b. At the beginning of the resident’s program, residency program directors (RPDs) must document an individualized set of program competency areas, educational goals, and educational objectives (CAGOs) for each resident. In doing so, PGY2 residencies in advanced areas of pharmacy practice must draw upon the program competency areas, educational goals, and educational objectives that have been developed by ASHP and approved by the Commission on Credentialing specifically for that practice area (e.g., critical care, health-system pharmacy administration, geriatrics, oncology, ambulatory care). RPDs may create additional program CAGOs that reflect the site’s strengths.

For PGY2 residencies in advanced areas of clinical pharmacy practice for which ASHP has not developed a complete set of competency areas, educational goals, and educational objectives, a generic set of program competency areas, educational goals, and educational objectives (Program Competency Areas, Educational Goals, and Educational Objectives for PGY2 Residencies in an Advanced Area of Pharmacy Practice) is available. This generic set of advanced clinical practice goals and objectives is provided as a required framework for programs that must develop their own Standard-mandated, area-specific, complete set of program competency areas, educational goals, and educational objectives. Also, RPDs for programs in non-clinical practice areas lacking ASHP-developed program competency areas, educational goals, and educational objectives must develop a complete set for their residencies. In both cases, RPDs must provide ASHP’s Accreditation Service Office their complete set of program competency areas, educational goals, and educational objectives at the time of application.

These competency areas, educational goals, educational objectives must be reviewed by the ASHP Commission on Credentialing before the application for accreditation status will be accepted.

Proposal Review Process

Requests for recognition of a PGY2 residency program in a new advanced area of pharmacy practice shall be sent to the Accreditation Services Office of ASHP (asd@ashp.org) for initial review. If the Accreditation Services Office (ASO) and the ASHP Commission on Credentialing (COC) agree that the request for recognition can proceed to the next level of consideration, the ASO will communicate this decision to the organization and the Criteria for Recognition of a Novel PGY2 Residency in a New Advanced Area of Pharmacy Practice and Demonstration Approval Process will be explained and initiated. Organizations will be requested to supply the following information for review by the COC:

a. Formal letter of request and describing the purpose of the novel PGY2 residency program.

b. Describe and provide evidence (references as applicable) the new advanced area of pharmacy practice meets the following novel PGY2 Criteria:
   i. demonstrates that the care of patients and their safety will be improved through recognition of education in that discipline;
   ii. is sufficiently distinct from other ASHP-approved advance areas of pharmacy practice based on major concepts in medical science and the delivery of patient care;
iii. represents a new or well-defined field of pharmacy practice not currently represented;

iv. offers educational content that cannot be incorporated within established residency programs;

v. will generate sufficient interest and resources to establish the critical mass of quality residency programs with long-term commitment for successful integration of the graduates in the health care system nationally; and,

vi. is recognized as the primary pathway to the competent preparation of pharmacists in the new advanced area of pharmacy practice.

c. List of citations to published articles in specialty area/topic and statements/data of need.

d. Proposed Program Structure.

e. Subject matter/disease state Gap Analysis and a crosswalk of proposed appendices with relevant approved and existing PGY2 programs.

f. Copy of the proposed PGY2 residency program director CV and APR Form.

The organization’s supporting documentation and proposal for review of a novel PGY2 residency program in an advanced area of pharmacy practice must be supplied to the ASO by a deadline set by ASO and will be presented to the next regularly scheduled COC meeting (March or August). Following a review by the COC of the proposal and associated documents, the organization will be notified of the COC decision to accept or deny the request for review of a PGY2 in a novel advanced area of pharmacy practice.

Proposals that are accepted will begin a process of collaborating with the ASO and identified COC members in the development of a set of program competency areas, educational goals, and educational objectives (CAGOs) and appendix (if applicable) specific to this novel PGY2 program. Once finalized, the CAGOs and appendix will be reviewed and considered for approval at the next possible COC meeting (March or August). Following COC approval, the proposing organization shall submit an application for accreditation (i.e., pre-candidate) along with the residency program director credentials, and will now begin the novel PGY2 Demonstration phase. The organization can begin the recruitment process for its first resident at this time. ASO will publish the approved CAGOs on the ASHP website following ASHP Board of Director approval.

ASO will guide the program through the Demonstration PGY2 requirements for review and accreditation. The maximum length of initial accreditation for all Demonstration PGY2 programs shall be no longer than 4 years. Transition from Demonstration status to a fully approved PGY2 advance practice area will not occur until, and if accreditation beyond, the initial period is granted by the COC and a review of required documentation submitted during the demonstration period has been approved.

**Sustainability and Relevance of the Novel PGY2 Residency**

The COC shall have the right to review and determine the continued viability of any recognized and accredited novel PGY2 residency program on a cyclical basis following an update of the PGY2 residency accreditation standard and CAGOs and a review of relevancy to the profession and these set criteria.